EUCTR2011-000092-13-GB进行中（未招募）1 期
A trial aimed at enhancing immunity to Influenza in elderly individuals through reversal of immune senescence mediated by herpes virus infection. - ASPIRE - A Study Promoting the Influenza Response in the Elderly v1
未提供0 个研究点开始时间: 2011年4月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria will be aged 65 years or above, CMV seropositive, a T cell response of over 0.5% at randomisation, relevant HLA-type, good renal function (eGFR>50ml/min).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Exclusion criteria will include unable to provide consent, on medication that may alter immune function, significant chronic illness as assessed by clinical team as this could affect ability to cooperate with the trial and may alter immune competence, history of a cardiovascular event in the past 6 months, and if the GP considers inappropriate to take part.
研究者
相似试验
已完成
不适用
Influenza vaccination strategies in haematological cancersInfluenza vaccinationHaematological malignancyInfection - Other infectious diseasesCancer - MyelomaCancer - Leukaemia - Chronic leukaemiaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12622000454774Peter MacCallum Cancer Centre130
尚未招募
4 期
A trial to study role of influenza vaccine in reducing heart attack, stroke, hospitalisation and death in patients of heart failure.CTRI/2016/07/007081McMaster University3,500
已完成
不适用
Antibody Response to Influenza Vaccine in Patients With SarcoidosisPulmonary SarcoidosisNCT00828828Shahid Beheshti University of Medical Sciences49
已完成
不适用
Trial of immunogenicity of a monovalent influenza A (H1N1) 2009 vaccinePrevention of influenzaJPRN-UMIN000002943ational Hospital Organization Headquarters200
已完成
3 期
Safety and Immunogenicity of the Butantan Quadrivalent Influenza VaccineInfluenza, HumanNCT03927131Butantan Institute5,822